Table 1
Component: ALC-0315 | Molecular weight: 766.27 | Reported molar entry: 35.6 | Calculated mass: Not calculated
sales@dcchemicals.com
PyCB lipid
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Table 1
Component: PyCB lipid | Molecular weight: 929.42 | Reported molar entry: 44.4 | Calculated mass: Not calculated
Table 1
Component: DSPC | Molecular weight: 790.15 | Reported molar entry: 20 | Calculated mass: Not calculated
Table 3
Parameter: Assembly method | Reported procedure / limitation: Ethanol dilution is explicitly reported; exact phase ratio, mixing rate and assembly-buffer pH are not specified. | Source: SI section 2.1
Table 3
Parameter: Recipe selection | Reported procedure / limitation: PyCB:ALC-0315 ratio optimized to 5:4, followed by DSPC optimization to 20%; final rounded composition 44.4:35.6:20 in that order. | Source: Main Fig. 1 and optimization text
Table 3
Parameter: Screen versus final recipe | Reported procedure / limitation: The initial screening entry uses 45% PyCB; final ThrCo uses 44.4%. | Source: Main Results; not combined into one exact recipe
Table 3
Parameter: N/P and processing | Reported procedure / limitation: Exact N/P, phase ratio, mixing flow and assembly-buffer pH are not established in the reviewed article/SI passages. | Source: No generic LNP protocol is substituted
Table 3
Parameter: Identity-dependent calculations | Reported procedure / limitation: A final ThrCo mass recipe is withheld pending resolution of the supplied PyCB structural / salt molecular-weight basis. The existing product identity fields are retained. | Source: Identity limitation; comparator mass calculation remains available
Table 4
Measurement / batch: Final ThrCo | Reported result: Approximately 200 nm | Evidence context: Main Fig. 3 characterization
Table 4
Measurement / batch: Composition dependence | Reported result: Initial zero-PyCB screen had encapsulation 25.23%; increasing PyCB to 67.5% reduced translation | Evidence context: Main optimization Results; not final ThrCo encapsulation
Table 4
Measurement / batch: Particle stability | Reported result: Particle size followed in PBS at 37 °C for 48 h and in serum-containing conditions | Evidence context: Main characterization; size stability alone does not prove preserved RNA expression
Table 5
Experiment and dose: Lipid-label distribution C57BL/6 mice; IV study dose 5 µg RNA/mouse; DiR lipid tracer | Readout and comparator: Readout: 6 h Comparator: ALC-0315 four-component study control | Result and source: Liver tracer signal was 30.9% of comparator; spleen signal was 2.6-fold higher. These tracer results are not the luciferase-expression fold change. Fig. 2J–M; n=3
Table 5
Experiment and dose: Functional reporter expression Same study context; luciferase mRNA | Readout and comparator: Readout: 6 h Comparator: ALC-0315 four-component study control | Result and source: Spleen luciferase expression was 4.5-fold higher. Cy5 RNA tracking and DiR lipid tracking are separate measurements. Fig. 2J–M; n=3
Table 5
Experiment and dose: Alternative spleen formulations Luciferase mRNA 0.25 mg/kg IV | Readout and comparator: Readout: 6 h Comparator: 18PA and 93-O17O study formulations | Result and source: Reported spleen expression was 42.1-fold and 9.3-fold higher, respectively. Comparator compositions differ. SI Fig. S6
Table 5
Experiment and dose: Cell uptake and expression DC2.4 cells; labeled / reporter RNA 1 µg/mL | Readout and comparator: Readout: 3 h uptake; later 24 h expression assay Comparator: Study formulations and inhibitor controls | Result and source: Uptake and translated reporter expression were measured independently; inhibitor responses do not establish an exclusive entry route. Main mechanistic experiments
Table 5
Experiment and dose: Formulated-RNA storage ThrCo formulations stored at 4 °C for 48 h or −80 °C for 1 week | Readout and comparator: Readout: Expression after storage Comparator: Fresh particles and four-component study control | Result and source: Expression remained comparable under the reported cold-storage conditions. A separate 37 °C / 24 h comparison favored ThrCo over the benchmark. SI Fig. S5D–G
Table 5
Experiment and dose: Repeat administration 5 µg RNA IV once weekly: EGFP cargo for the first two doses, luciferase for the third | Readout and comparator: Readout: 24 h after the final dose Comparator: Four-component study control | Result and source: ThrCo retained reporter expression more effectively in the reported repeat-dose comparison. Cargo-switch design and dose schedule are part of this result. Main repeat-dose study
Table 5
Experiment and dose: Acute liver markers Male and female mice; IV RNA 1 or 5 mg/kg | Readout and comparator: Readout: 24 h Comparator: Study control LNPs | Result and source: ALT/AST were assessed; no significant increase at 1 mg/kg in the reported comparison. This does not establish long-term or repeated high-dose safety. Fig. 2N–Q; n=4